Partnership with QIMR Berghofer targets oesophageal cancer
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- June 2020 Quarterly Activities Report and Appendix 4C
- PromarkerD Intellectual Property portfolio expands
- Appendix 3Y - Directors on-market purchase of shares
- Big pharma clinical study validates PromarkerD kidney test
- Updated Investor Presentation
Later from Proteomics International Laboratories
- First distribution agreement for PromarkerD immunoassay
- Proteomics International raises $6m in successful Placement
- September 2020 Quarterly Activities Report and Appendix 4C
- Completion of Placement and Appendix 2A
- Proteomics receives $1.1 million in R&D tax incentive
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories